<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04900051</url>
  </required_header>
  <id_info>
    <org_study_id>2020-08-016</org_study_id>
    <nct_id>NCT04900051</nct_id>
  </id_info>
  <brief_title>Clinical Efficacy and Safety of Fecal Microbiota Transplantation</brief_title>
  <official_title>Clinical Efficacy and Safety of Fecal Microbiota Transplantation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Keimyung University Dongsan Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Keimyung University Dongsan Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Changes in the fecal microbiota are known to be involved in the etiology of several diseases.&#xD;
      The purpose of this study is to evaluate the effectiveness and safety of fecal microbiota&#xD;
      transplantation (FMT) in diseases known to be associated with intestinal microbial inbalance.&#xD;
      .&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This registry will prospectively enroll 300 patients who undergo fecal microbiota&#xD;
      transplantation(FMT) at 3 clinical center (Yeungnam university mecial center, Kyungpook&#xD;
      national university hospital, Keimyung university dongsan medical center). Feces received&#xD;
      from healthy donors are prepared as frozen feces according to a standardized protocol, and&#xD;
      transplanted to recipients within 3 months. Next generation sequencing(NGS) is used to check&#xD;
      the characteristics of the fecal microbiota of the donor stool, and to evaluate the efficacy&#xD;
      by checking the change in the fecal microbium of recipient before and after transplantation.&#xD;
      The data is documented for following diseases known to be related to microbium imbalance.&#xD;
&#xD;
        1. Recurrent or Refractory CDI Abdominal symptoms questionnaires, blood laboratory&#xD;
           test(CBC, CRP, protein/albumin, AST/ALT, GTP, Total bilirubin/Direct bilirubin)&#xD;
&#xD;
        2. Irritable bowel syndrome, Functional dyspepsia Abdominal symptoms questionnaires, IBS&#xD;
           diagnosis and food-related questionnaires, blood laboratory test(CBC, CRP,&#xD;
           protein/albumin, AST/ALT, GTP, Total bilirubin/Direct bilirubin)&#xD;
&#xD;
        3. Inflammatory Bowel Disease Abdominal symptoms questionnaires, blood laboratory test(CBC,&#xD;
           CRP, protein/albumin, AST/ALT, GTP, Total bilirubin/Direct bilirubin), fecal&#xD;
           calprotectin, Colonoscopic examination(Mayo endoscopic subscore, CD-SES)&#xD;
&#xD;
        4. Non-alcoholic steatohepatitis, NASH Abdominal symptoms questionnaires, blood laboratory&#xD;
           test(CBC, CRP, protein/albumin, AST/ALT, GTP, Total bilirubin/Direct bilirubin), BMI&#xD;
           check&#xD;
&#xD;
        5. Obesity Abdominal symptoms questionnaires, blood laboratory test(CBC, CRP,&#xD;
           protein/albumin, AST/ALT, GTP, Total bilirubin/Direct bilirubin), BMI check&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 24, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2023</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>6 Months</target_duration>
  <primary_outcome>
    <measure>Set up a FMT registry</measure>
    <time_frame>3 years</time_frame>
    <description>Set up a registry of FMT in diseases known to be associated with intestinal microbial imbalance</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Patient outcome of FMT</measure>
    <time_frame>6 month</time_frame>
    <description>Compare the severity of diseases, any adverse event before and after FMT</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Developing biobank of FMT</measure>
    <time_frame>3 Years</time_frame>
    <description>Collect the study sample of microbium from donors and recipients</description>
  </secondary_outcome>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Fecal Microbiota Transplantation</condition>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood laboratory test(CBC, CRP, protein/albumin, AST/ALT, GTP, Total bilirubin/Direct&#xD;
      bilirubin), Fecal calprotectin, Stool&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        -  Hospitalized and outpatient aged from 18 to 80 years old&#xD;
&#xD;
          -  Those who agrees after hearing the explanation on the efficacy and safety of fecal&#xD;
             microbiota transplantation&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Those who have been diagnosed with disease to be studied and do not respond to exist&#xD;
             treatments&#xD;
&#xD;
               1. Ulcerative colitis, Crohn disease : Patient who does not responding to anti- TNF&#xD;
                  treatment for more than 3 month.&#xD;
&#xD;
               2. Irritable bowel syndrome, Functional dyspepsia : Patient who does not responding&#xD;
                  to pharmacological therapies and serotonin uptake inhibitor for more than 6&#xD;
                  month.&#xD;
&#xD;
               3. Recurrent of Refractory CDI, NASH, Obesity : Patient who does not responding to&#xD;
                  treatment for more than 6 month.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Neutrophil (&lt;0.5 x 10*9/L)&#xD;
&#xD;
          -  Leukocytosis (&gt; 30.0 x 10*9/L)&#xD;
&#xD;
          -  Toxic megacolon confirmed in abdomen Xray&#xD;
&#xD;
          -  Pregnant or lactating women&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lee Yoo Jin, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Keimyung University Dongsan Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yoo Jin Lee, Professor</last_name>
    <phone>+82-53-250-7163</phone>
    <email>doctorlyj@naver.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>KeimyungUniversity</name>
      <address>
        <city>Daegu</city>
        <state>Jung-gu</state>
        <zip>700-712</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yoo Jin Lee</last_name>
      <phone>+82-250-7088</phone>
      <email>doctorlyj@naver.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>March 31, 2021</study_first_submitted>
  <study_first_submitted_qc>May 19, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 25, 2021</study_first_posted>
  <last_update_submitted>May 19, 2021</last_update_submitted>
  <last_update_submitted_qc>May 19, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 25, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Keimyung University Dongsan Medical Center</investigator_affiliation>
    <investigator_full_name>YooJin Lee</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

